Horizon Discovery today announces that it has appointed Dr Rob Howes, formerly Head of Assay Development and Screening at Vernalis plc, as its new R&D Director.
Rob has over 10 years experience in Oncology research and development and brings to the company experience that covers target validation. new lead generation and preclinical development.
He holds a PhD in Biology from the University of Cambridge and held post-doctoral positions at Stanford University, California and the University of Cambridge. He is the author of 15 peer-reviewed papers, many of which are on small molecule drug discovery and, has spoken at many international conferences with a focus on assay development and screening of oncology targets.
He takes up his new post from 1st June 2008 and will be responsible for: managing the company’s gene engineering facility in Torino; liaising with screening service partners Caliper Life Science & Hypoxium and; delivering on commerical R&D contracts in place with Cancer Research UK. Genentech and the Migrating Cancer Stem Cell’s Framework-6 consortium.
Rob Howes says “I am very pleased to join Horizon Discovery at this exciting time in the company’s development. Having worked with Chris Torrance previously at Vernalis, I know we make a great team who along with the company’s other principles can take Horizon to the next level”.